MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR-342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation (56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer (12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR-342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes.
Introduction
MicroRNAs are small (typically 22 nucleotides in length) RNAs that influence gene expression networks by repressing target messenger RNAs by specific basepairing interactions (Bartel, 2004; He and Hannon, 2004) . A growing body of literature indicates that microRNAs are dysregulated in human malignancies and it has been proposed that some microRNAs may have oncogenic or tumor suppressor functions (Zhang et al., 2007) . Consistent with this idea, both overexpression and silencing of specific microRNAs have been described in a number of cancer types, including colorectal cancer (Michael et al., 2003; Bandres et al., 2006; Cummins et al., 2006; Volinia et al., 2006; Wijnhoven et al., 2007) .
As a first step toward understanding dysregulation of the microRNA regulatory network in cancer, we have assessed microRNAs that undergo silencing in colorectal cancer, as these represent candidate tumor suppressors. We hypothesized that one mode of transcriptional silencing of microRNAs may be epigenetic mechanisms related to the aberrant DNA methylation of 5 0 -regulatory regions, as has been observed for many 'conventional' tumor suppressor genes (Toyota et al., 1999; Kondo and Issa, 2004; Kim et al., 2006) . In fact, examples of DNA methylation-based regulation of microRNA genes by proximal CpG islands have been recently described (Saito and Jones, 2006; Brueckner et al., 2007; Lujambio et al., 2007) .
Many microRNAs, however, are encoded in introns of protein-encoding genes (and subsequently excised from a primary transcript in common with the host gene) (Rodriguez et al., 2004; Kim and Kim, 2007; Saini et al., 2007) , and thus they would be predicted to be susceptible to transcriptional repression by aberrant methylation of a CpG island located in the host gene 5 0 UTR. We hypothesized that in some cases transcriptional regulation of microRNA gene expression might be achieved by epigenetic alterations of host gene regulatory elements, which could be located far from the microRNA locus. We now provide evidence for this mechanism by showing that the intronic microRNA hsa-miR-342 is silenced in the majority of colorectal cancers by methylation of a CpG island in the 5 0 aspect of its host gene, Ena/Vasp-like (EVL). We also find that reconstitution of hsa-miR-342 activity induces apoptosis in colorectal cancer cells, suggesting a possible tumor suppressor role for this microRNA in colorectal cancer.
Results hsa-miR-342 is encoded in an intron of the EVL gene and is commonly silenced in colorectal cancer hsa-miR-342 is an intronic microRNA that was found to be underexpressed in colorectal cancer in a global screen for microRNA dysregulation based on deep sequencing of microRNA populations from colorectal cancer and matched normal colorectal epithelial tissues (Cummins et al., 2006) . hsa-miR-342 captured our attention because of the presence of a dense CpG island in the 5 0 -upstream region of its host gene, EVL ( Figure 1a ). We first assessed the expression of hsa-miR-342 using qRT-PCR (quantitative reverse transcription-PCR) in primary colorectal cancers and matched normal colorectal mucosa samples (N ¼ 19) that represented tissue collections from two independent sources ( Figure 1b) . We found suppression of hsa-miR-342 expression (defined as >20% decreased expression in the primary cancer versus the normal mucosa) in 58% of the cancers (N ¼ 11/19). The other cancers either showed minimal change in hsa-miR-342 expression (21%, N ¼ 4/19) or in a few cases showed an increase in expression of >20% in the cancer (21%, N ¼ 4/19).
Having confirmed that the expression of hsa-miR-342 is suppressed in a large subset (58%) of colorectal cancers, we measured expression of its host gene, EVL, in the same samples to determine whether there may be a coordinated regulation of silencing. EVL expression was found to be suppressed in the majority (14 out of 19) of cancer samples relative to matched normal mucosa (Figure 1b ). There was a positive correlation between suppression of EVL and suppression of hsa-miR-342 expression in cancer samples (Pearson's correlation coefficient ¼ þ 0.41; P-value ¼ 0.075). As an additional approach for testing for a correlation between EVL and hsa-miR-342 expression, we measured the levels of both RNAs across a panel of 28 cancer cell lines (Figure 1c; Supplementary Figure S1 ). Expression of EVL and hsa-miR-342 was positively correlated (Pearson's correlation coefficient ¼ þ 0.547; P-value ¼ 0.003) (Supplementary Figure S1) . Moreover, in five out of six colorectal cancer cell lines, EVL and hsa-miR-342 expression was substantially suppressed (reflected by higher normalized cycle threshold (that is, DCt) values) relative to cell lines derived from other types of cancer ( Figure 1c) Repression of hsa-miR-342 and EVL is associated with aberrant methylation of the EVL/hsa-miR-342 promoter To determine the mechanism responsible for EVL/ hsa-miR-342 suppression in colorectal cancer, we used methylation-specific PCR (MSP) to assess the methylation status of the CpG island immediately upstream of the EVL gene ( Figure 1a ) in a panel of seven colorectal cancer cell lines (VACO411, AA/C1/SB10, HT-29, RKO, SW48, VACO703 and VACO400; Figure 2a ) and three colorectal adenoma cell lines (AA/C1, RG/C2 and VACO235; data not shown). Six of the seven colorectal cancer cell lines were found to carry methylated EVL (Figure 2a ), and two of the three colorectal adenoma cell lines (RG/C2 and VACO235) were found to have methylated EVL (data not shown). Importantly, the single colorectal cancer cell line (VACO400) that was unmethylated was also the one that did not show suppression of EVL and hsa-miR-342 expression (indicated by an asterisk in Figure 2a and Figure 1c) . Furthermore, in colorectal cancer lines showing methylation at the EVL CpG island, with the exception of AA/ C1/SB10 and VACO703, there were no unmethylated alleles detected (Figure 2a ). Bisulfite sequencing of EVL in VACO411 and AA/C1/SB10 confirmed dense methylation in the EVL/hsa-miR-342 promoter in VACO411 and a mixture of methylated and unmethylated clones in AA/C1/SB10 (Figure 2b ). Approximately 50% of the clones in AA/C1/SB10 showed >50% of the CpGs methylated, and the other 50% of the clones showed 0-25% of the CpGs methylated (Figure 2b ).
DNA methylation at the EVL/hsa-miR-342 locus is infrequent in non-colorectal cancer cell lines Next we assessed whether aberrant methylation of EVL/hsa-miR-342 is present in other tumor types by examining DNA isolated from a panel of 40 additional cancer cell lines derived from a variety of non-colorectal cancer types. Remarkably, only one out of 40 of the non-colorectal cancer derived lines showed some evidence of methylation (Supplementary Figure S2 and Supplementary Table S1 ). In the single cell line where methylation was detected (a lung cancer line), only partial methylation was present.
Inhibition of DNA methylation induces the expression of hsa-miR-342 and EVL To determine whether methylation of the EVL CpG island mediates silencing of hsa-miR-342 and EVL expression, the colorectal cancer cell line VACO411 was treated with a regimen of 5-aza-2 0 -deoxycytidine and Trichostatin A followed by measurement of EVL and hsa-miR-342 expression by TaqMan-based qRT-PCR. Treatment with low-dose 5-aza-2 0 -deoxycytidine
Cell Line Case number Most colorectal cancer cell lines (indicated by gray bar) had suppressed levels of EVL/hsa-miR-342 relative to other human cancer cell lines. The one colorectal cancer cell line that had levels of hsa-miR-342 similar to that of non-colorectal cancer cell lines (VACO400, indicated by an *) was subsequently found to be unmethylated at the EVL/hsa-miR-342 promoter region (see Figure 2a) .
(200 nM) and Trichostatin A (300 nM) led to the appearance of unmethylated EVL/hsa-miR-342 as detected by the MSP assay (Figure 2c ). This was associated with induction of expression of both hsa-miR-342 and EVL transcripts in three independent experiments (Figure 2c ). The p16/CDKN2A gene promoter, which is known to be methylated in colorectal cancer and is used as a positive control here (Myohanen et al., 1998) , was also induced (Figure 2c ). These results are consistent with a model in which DNA methylation of the EVL upstream region represses the expression of both EVL and hsa-miR-342.
The EVL/hsa-miR-342 locus is frequently methylated in colorectal adenomas and adenocarcinomas Next we examined the methylation status of EVL/ hsa-miR-342 in primary adenomas and adenocarcinomas, as well as in normal colorectal mucosa (Figure 2d ). Sixty-seven percent (N ¼ 6/9) of colorectal adenomas were found to carry methylated EVL/hsa-miR-342. In primary colorectal adenocarcinomas, 86% (N ¼ 36/42) of the tumors were found to carry methylated EVL/hsamiR-342. Interestingly, we found that the incidence of methylated EVL/hsa-miR-342 in normal mucosa varied depending on whether it was derived from canceraffected colon or from colorectal biopsies taken from individuals with colonoscopically normal colons (referred to here as 'cancer-free controls'). Using an MSPbased assay, we found methylated EVL/hsa-miR-342 in 12% (N ¼ 2/16) of normal mucosa from cancer-free controls, whereas 56% (N ¼ 9/16) of histologically normal colorectal mucosa from individuals with concurrent colorectal adenocarcinoma had MSP-detectable EVL/hsa-miR-342 locus methylation (P-value ¼ 0.023, Fisher's exact test) (Figure 2d ). These results suggest the possibility of a colorectal mucosal 'field defect' related to aberrant methylation.
Bisulfite sequencing of the EVL/hsa-miR-342 locus in representative samples revealed little methylation in the DNA from normal colorectal mucosa from cancer-free controls, and dense methylation in the cancer DNA (Figure 3) . None of the clones from the normal samples showed dense methylation (defined as >50% of CpGs methylated). The histologically normal colorectal mucosa from individuals with colorectal cancer showed an intermediate proportion of methylated CpGs, which was consistent with the MSP assay results (Figure 3 ). hsa-miR-342 reconstitution induces apoptosis in colorectal cancer cells The observed silencing of hsa-miR-342 in colorectal cancer raised the possibility that this microRNA may contribute to tumor suppressor activity in the colon. Tumor suppressor genes are commonly known to regulate cell proliferation, apoptosis or DNA repair. We examined the biological consequence of methylation of the EVL/hsa-miR-342 locus by transfecting a synthetic hsa-miR-342 mimic into the colorectal cancer cell line HT-29 (which was shown earlier to be densely methylated at the EVL/hsa-miR-342 locus; Figure 2a ).
There was no effect of hsa-miR-342 reconstitution on cell proliferation (Figure 4a ). However, hsa-miR-342 reconstitution resulted in a marked increase in apoptosis, whereas transfection of negative control microRNA mimics had no effect (Figures 4b and c) . These results suggest that the targets of hsa-miR-342 may be antiapoptotic factors and that silencing of hsa-miR-342 expression may promote colorectal cancer formation by enhancing antiapoptotic pathways.
Candidate gene targets of hsa-miR-342 derived from computational predictions Given that hsa-miR-342 is silenced in colorectal cancer, and that reconstitution of hsa-miR-342 activity induces apoptosis in the HT-29 cell line, we reasoned that its target(s) might be overexpressed in colorectal cancer and have function related to antiapoptotic pathways. We assembled a list of the predicted targets in common to hsa-miR-342 target outputs from three microRNA target prediction algorithms: miRanda (Griffiths-Jones et al., 2006), TargetScan (Lewis et al., 2005) and PicTar (Krek et al., 2005) . Next, we conducted a literature survey to determine whether the 13 targets predicted in common by all three computational algorithms were known to be overexpressed in colorectal cancer or had roles consistent with antiapoptotic activity (Supplementary Table S2 ). Platelet-derived growth factor receptor, a polypeptide (PDGFRA) and RAS p21 protein activator (GTPase activating protein) 1 (RASA1) satisfied both these criteria and represent candidate targets of hsa-miR-342. Further evaluation of these genes with regards to their role in hsa-miR-342 mediated apoptosis is warranted.
As a complementary approach for identifying regulatory targets of hsa-miR-342 for future studies, we queried the Oncomine cancer profiling research database (www.Oncomine.org) (Rhodes et al., 2007) to identify genes that are (a) overexpressed in colorectal cancer based on results from three relevant gene expression profiling studies (Alon et al., 1999; Notterman et al., 2001; Zou et al., 2002) and (b) PicTar-predicted targets of hsa-miR-342. Eleven genes satisfied these criteria and are presented in Supplementary Table S3 .
Discussion
In this study, we confirmed that silencing of hsa-miR-342 is a common event in colorectal cancer and provided evidence for coordinate epigenetic silencing of an intronic microRNA and its host gene in human cancer. Given that roughly half of microRNA genes are located in introns (Rodriguez et al., 2004; Kim and Kim, 2007; Saini et al., 2007) , we suggest that this mode of coordinate silencing may represent a more general mechanism of microRNA suppression in human cancer.
Our data also suggest that methylation of the EVL/hsamiR-342 locus is an early event in colorectal carcinogenesis, given that it is detectable in 67% of adenomas, as well as in 56% of histologically normal colorectal mucosal specimens from patients with concurrent colorectal cancer.
Based on these observations, we propose that the methylated DNA corresponding to the EVL/hsa-miR-342 locus may merit further investigation as a biomarker for non-invasive disease detection or risk prediction for colorectal cancer, especially in light of its apparent specificity for colorectal cancer.
With respect to carcinogenesis, the data suggest a model in which the aberrant methylation of EVL/hsa-miR-342 precedes histologically apparent neoplastic alterations in the colon and leads to an early expansion of precancerous progenitor cells carrying methylated CpG islands at the EVL/hsa-miR-342 locus. The presence of methylation of EVL/hsa-miR-342 in normal appearing colorectal mucosa may reflect an acquired, early epigenetic change in the pathogenesis of colorectal cancer. Alternatively, it could also be the consequence of clonal expansion of rare, normal colorectal epithelial cells that carry a methylated EVL/hsa-miR-342 locus as a part of their normal physiological state (Ohm and Baylin, 2007; Widschwendter et al., 2007) . Given that EVL and hsa-miR-342 are coordinately silenced, we cannot determine a priori whether suppression of EVL, hsa-miR-342 or both is the relevant event in colorectal carcinogenesis. EVL is a member of the Ena/VASP protein family, which are actin-associated proteins involved in a variety of processes related to Results of EVL/hsa-miR-342 MSP assay using primers that amplify methylated (M) or unmethylated (U) alleles specifically. Methylation of the EVL/hsa-miR-342 locus was observed in six out of seven colorectal cancer cell lines tested. DNA from VACO411, HT-29, RKO and SW48 cell lines showed only methylated EVL, whereas AA/C1/SB10 and VACO703 cell lines showed both methylated and unmethylated EVL. VACO400 (indicated by an *) was unmethylated at the EVL/hsa-miR-342 locus. PBL DNA was used as the unmethylated control. Methylase SssI treated DNA was used as the methylated DNA control. (b) Bisulfite genomic sequencing of EVL/hsa-miR-342 promoter CpG island in colorectal cancer cell lines. The sequencing results are shown schematically with each CpG represented as a lollipop structure. The white lollipops are unmethylated CpGs and the black lollipops are methylated CpGs. Each horizontal strand is one clone. The PBL sample is DNA from PBL and is a control for unmethylated EVL/hsa-miR-342. The VACO411 and AA/C1/SB10 samples are DNA from those cell lines, respectively. (c) Effect of 5-aza-2-dC þ Trichostatin A treatment on EVL CpG island methylation and expression of EVL and hsa-miR-342. Results of EVL/hsa-miR-342 MSP assay using primers that specifically amplify methylated (M) or unmethylated (U) alleles are shown after mock treatment or after treatment with 5-aza-2-dC and Trichostatin A. (Top) In VACO411 colorectal cancer cells, 5-aza-2-dC (200 nM) in conjunction with Trichostatin A (TSA; 300 nM) results in a decrease in methylation of the EVL/hsa-miR-342 locus. (Bottom) Reduction of EVL upstream region CpG island methylation induces the expression of both EVL and hsa-miR-342 in the VACO411 cell line (values reflect the average of three biological replicates, ± s.e.m.). The p16/CDKN2A gene, used here as a positive control known to be methylated in colorectal cancer, was also induced (value reflects the average of two biological replicates, ± s.e.m.). EVL, hsa-miR-342 and p16/CDKN2A RNA levels were measured using TaqMan-based qRT-PCR assays. cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells (Krause et al., 2003) . It is possible that EVL could function as a tumor suppressor through effects on cell shape or motility.
In this study, we have provided the evidence that hsamiR-342 can induce apoptosis in colorectal cancer cells. An important caveat, however, is that we cannot exclude the possibility that the phenotype observed with hsa-miR-342 reconstitution is due to off-target effects beyond the normal physiological function of this microRNA. Nonetheless, our observation that reconstituting hsa-miR-342 activity in the HT-29 colorectal cancer cell line results in apoptosis provides a plausible basis for why silencing of this microRNA would promote the formation of colorectal cancer. Further experiments will be needed, however, to determine whether these proapoptotic effects are reflective of hsa-miR-342 being a bona fide microRNA tumor suppressor in colorectal cancer.
Our survey of EVL/hsa-miR-342 methylation in a large cancer cell line panel indicates that methylation at this locus is largely restricted to colorectal cancer. Given that hsa-miR-342 is widely expressed in diverse, ). There was no statistically significant difference between groups using Student's t-test and a P-value threshold of Po0.05. (B) Apoptosis as measured by an assay based on cytoplasmic histone-associated DNA fragments (Cytodeath ELISA, Roche) 72 h after transfection with microRNA mimics. Results are expressed as mean ± s.e.m. and reflect data from six biological replicates. non-colorectal cancer cell types (Figure 1c ) without apparent deleterious effects, an attractive interpretation is that expression of hsa-miR-342 has a synthetic lethal genetic interaction with other alteration(s) associated with colorectal carcinogenesis. Although the messenger RNA targets of hsa-miR-342 are not known, the identification and validation of such targets could be useful for determining the potential value of delivery of hsa-miR-342 to colorectal cancers as a cancer-specific therapeutic strategy.
Materials and methods

Clinical materials
Normal or colorectal tumor samples were collected from patients treated at Vanderbilt University Medical Center (Nashville, TN, USA) and Case Western Reserve University/ University Hospitals of Cleveland (Cleveland, OH, USA), as well as from the Cooperative Human Tissue Network as either paraffin-embedded, formalin-fixed tissues or fresh frozen tissues. The studies were conducted using protocols approved by the Institutional Review Board of each institution.
Methylation analysis was conducted on 42 colorectal cancers, 9 colorectal adenomas and 16 samples of grossly normal mucosa in patients with and without colorectal cancer. None of the patients had a clinically apparent polyposis syndrome or hereditary nonpolyposis colorectal cancer.
Extraction of DNA/RNA and description of cell line RNA panel Description of genomic DNA and total RNA extraction from cultured cells and tissues can be found in Supplementary Materials and methods. A listing of commercial cell line RNAs used in this study can be found in Supplementary Table S4 .
Quantitative reverse-transcription PCR for EVL, p16/CDKN2A and hsa-miR-342 Total RNA was reverse transcribed using the TaqMan microRNA Reverse Transcription Kit (for hsa-miR-342) or the High Capacity cDNA Reverse Transcription Kit (for EVL and p16/CDKN2A) following the manufacturer's protocol (Applied Biosystems Inc., Foster City, CA, USA). Detailed information on TaqMan assays used for real-time PCR is provided in Supplementary Materials and methods.
Genomic DNA methylation analysis Genomic DNA was modified with sodium bisulfite as described previously (Grady et al., 2001 ). Positive and negative controls, consisting of methylated DNA obtained from colorectal cancer cell lines and unmethylated DNA obtained from normal human peripheral blood lymphocytes were included with each round of bisulfite treatment and subsequent MSP analysis and bisulfite genomic sequencing. More detailed information about MSP analysis and bisulfite genomic sequencing is available in Supplementary Materials and methods.
Treatment with 5-aza-2 0 -deoxycytidine and Trichostatin A VACO411 cells were grown for 48 h before treatment with 5-aza-2 0 -deoxycytidine (Sigma-Aldrich Co., St Louis, MO, USA) dissolved in dimethyl sulfoxide. The cells were treated with 5-aza-2 0 -deoxycytidine (200 nM final concentration) for 48 h and then Trichostatin A (TSA; Sigma-Aldrich Co.) was added to the media (300 nM final concentration). The cells were then incubated for an additional 24 h before harvesting. DNA was extracted and analysed by bisulfite treatment followed by MSP using EVL/hsa-miR-342 primers as described above. RNA was isolated from identically treated cultures for qRT-PCR analysis. The control samples were treated with the dimethyl sulfoxide vehicle only.
Cell culture and microRNA mimic transfections Details of cell culture and microRNA mimic transfections are provided in Supplementary Materials and methods.
Cellular proliferation and apoptosis assays
Cell proliferation and apoptosis assays were carried out as detailed in Supplementary Materials and methods.
